Serum Insulin-Like Growth Factor-1 in Patients with De Novo, Drug Naïve Parkinson's Disease: A Meta-Analysis.
Serum Insulin-Like Growth Factor-1 in Patients with De Novo, Drug Naïve Parkinson's Disease: A Meta-Analysis.
复制标题
初治药物帕金森病患者血清胰岛素样生长因子 1：荟萃分析。
DOI：
10.1371/journal.pone.0144755
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Liu J
中科院分区：
文献类型：
--
作者：
Li DH;He YC;Quinn TJ;Liu J
据报道，胰岛素样生长因子-1（IGF-1）在帕金森氏病（PD）的环境中具有神经保护作用，并且对血清IGF-1水平与PD患者的可能关联越来越兴趣，因此，我们进行了元分析，我们进行了荟萃分析，以评估De NaT NaIn NaIn Naist na na na na na na na na na na na na na na na na na na na na na na na na na na na na na na na na na naish pd pd pd pd pd pd pd pd。
从1966年到2014年10月，PubMed，ISI Web of Science，Ovid，Embase和Cochrane库数据库被用于使用医学主观标题进行候选研究，而无需使用语言限制，并选择了子组分析和敏感性分析，以揭示在纳入的研究中进行的杂项。
在这项荟萃分析中，我们发现PD患者与健康对照组相比具有更高的血清IGF-1水平（摘要平均差异[MD] = 17.75，95％CI = 6.01，29.48）表明，异质性的来源是整个敏感性的一致性。
这项荟萃分析的结果表明，与健康对照相比，从头开始，不使用药物的PD患者的血清IGF-1水平明显更高。
Insulin-like growth factor-1 (IGF-1) is reported to be neuroprotective in the setting of Parkinson’s disease (PD), and there is increasing interest in the possible association of serum IGF-1 levels with PD patients, but with conflicting results. Therefore, we conducted a meta-analysis to evaluate the association of serum IGF-1 levels in de novo, drug naïve PD patients compared with healthy controls. Pubmed, ISI Web of Science, OVID, EMBASE, and Cochrane library databases from 1966 to October 2014 were utilized to identify candidate studies using Medical Subjective Headings without language restriction. A random-effects model was chosen, with subgroup analysis and sensitivity analysis conducted to reveal underlying heterogeneity among the included studies. In this meta-analysis, we found that PD patients had higher serum IGF-1 levels compared with healthy controls (summary mean difference [MD] = 17.75, 95%CI = 6.01, 29.48). Subgroup analysis demonstrated that the source of heterogeneity was population differences within the total group. Sensitivity analysis showed that the combined MD was consistent at any time omitting any one study. The results of this meta-analysis demonstrate that serum IGF-1 levels were significantly higher in de novo, drug-naïve PD patients compared with healthy controls. Nevertheless, additional endeavors are required to further explore the association between serum IGF-1 levels and diagnosis, prognosis and early therapy for PD.